BioCentury | Jan 7, 2020
Finance

BioIntervene takes on adenosine in pain, raises $30M

With IP from St. Louis University and NIH, BioIntervene raised a $30 million series A round from MPM Capital to bring what could be a first-in-class pain therapy into the clinic. The company plans to...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BC Innovations | Nov 21, 2019
Emerging Company Profile

ShapeTx: Shaping up RNA editing

With its RNAfix platform, Shape is developing therapeutics that are designed to edit RNA in vivo by hijacking an enzyme in the target cell that naturally converts one RNA base to another. The company raised...
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
BioCentury | Oct 7, 2019
Emerging Company Profile

Gene editing vets launch Korro to convert RNA bases

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA...
BC Innovations | Sep 12, 2019
Distillery Techniques

Beam co-founder describes base editors with reduced RNA editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy Beam Therapeutics co-founder J. Keith Joung and colleagues described cytosine and adenine base editors that could reduce off-target RNA editing compared with prior versions of the technologies. An...
BC Extra | Sep 4, 2019
Company News

Novartis’ early collaboration with NICE key to rapid response on Luxturna

In one of NICE’s fastest draft recommendations for a new therapy on the NHS, the HTA found gene therapy Luxturna from Novartis to be cost-effective to treat a rare genetic retinal disorder. Novartis’ offer of...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
Items per page:
1 - 10 of 1090